Americans spend about $3 trillion per year on healthcare, or about $10,000 per person per year. Despite these expenditures, Americans are worse off than their international counterparts with respect to infant mortality, life expectancy and the prevalence of chronic conditions. For comparable levels of individual care, Americans spent about 60% more than their overseas counterparts.
This paper proposes a new standards-based approach for fixing the inefficiencies plaguing the healthcare industry in the United States. As described herein, non-profit standards bodies would be established by Congress to bring a coordinated approach to healthcare for each of the top ten chronic diseases.
Such an approach would establish consistent priorities and practices across all of the components in the healthcare industry affecting these chronic diseases, including prevention, standards of care, areas of research emphasis and insurance guidelines.
The U.S. Healthcare Market Doesn’t Function Effectively
Looking at the components of the healthcare industry from standards of care to prices to insurance coverage to potential new treatments, virtually none of the relevant choices are transparent to the consumer. Hence, a well-functioning market in healthcare does not exist.
Equally troubling, none of components of the system work in lock-step. For example, the FDA could have indirectly required billions of dollars of research to be spent on a drug before it gets the FDA’s approval, only to find that the organizations that provide guidelines for care don’t promote its use and/or the insurance carriers don’t contribute towards its charges.
One indication of this dysfunction is that there is widespread variation in charges for the same medical procedures. For example, a study shows that, in California, an appendectomy can cost anywhere between $1,529 and $186,955 depending on where it was performed.
Equally telling, price differences for the same procedure exist even within a single healthcare center.
One way to think about the current system is depicted in the following chart:
As the chart implies, all of the components of the healthcare industry impact each other. However, they don’t work in lock-step to achieve a certain outcome. Moreover, the consumer is hard-pressed to make heads or tails of the best approach for his or her condition given that the relevant information for each component is hard to get. This is particularly true for chronic illnesses. Hence, the current system almost guarantees a misallocation of resources.
On the positive side, non-profit organizations such as the Michael J. Fox Foundation for Parkinson’s disease (MJFF) and the Basser Center at Penn Medicine for hereditary cancer have stepped up to fill the void of a consistent and sustained strategy in their respective fields.
Since 2000, MJFF has funded more than $750 million to pursue a cure for Parkinson’s disease. It is collaborating with literally scores of organizations with respect to funding, in-kind contributions, strategic input and research initiatives. It also provides extensive information to the public at no cost, including weekly video briefings, covering issues such as diagnosis and symptoms, living with Parkinson’s disease, treatment options and promising new research.
Similarly, in 2012, the Basser Center for BRCA was established with a $30 million gift to the University of Pennsylvania from alumni Mindy and Jon Gray. At the time, the FDA had denied a Citizen’s Petition I had filed to treat BRCA-related cancer as a separate category of cancer.
The Basser Center’s original charter focused on awarding grants to University of Pennsylvania faculty members and external investigators for research targeted to BRCA1 and BRCA2-derived cancers. Over time, Susan Domchek, MD, executive director of the Basser Center, became a national leader on the OlympiAD trials that led to the FDA approval of the first treatment for women with inherited breast cancer.
In furthering its mission, the Basser Center also awards the annual Basser Global Prize to an international expert and hosts educational seminars and conferences.
Despite some bright spots, the current healthcare system doesn’t work efficiently for individual purchase decisions. Accordingly, the roll-up of all healthcare practices and purchases on a national basis will highlight the areas with the greatest inefficiencies.
In broad terms, the cost of healthcare in the United States is approximately $3.0 trillion per year (or $10,000/person), including:
When looking for causation for these healthcare expenditures, there are many large targets including heart disease, diabetes, asthma, cancer, Alzheimer’s, Parkinson’s and Epilepsy.
Taken together, chronic diseases cause 7 of every 10 deaths in America. Moreover, about 25% of people with chronic diseases have some type of activity limitation such as needing help with dressing or bathing or being restricted from work or attending school.
By any measure, chronic diseases take a heavy toll on the nation’s health and wealth. For example, heart disease and stroke are estimated to cost over $430 billion per year. Diabetes costs are estimated to be about $175 billion per year. Alzheimer’s is estimated to add about $150 billion per year. And cancer adds over $200 billion per year. In total, well over 50% of the $3 trillion spent on health care each year is attributable to chronic diseases.
The logical question to ask is: “what is being done about it?” The answer is a quite a lot, but not very effectively or efficiently.
The FDA has been at the center of the process of new healthcare solutions for over a century.
The FDA has done a good job in achieving its legislative charter of ensuring that drugs and devices are safe and effective. For example, over the last 50 years, only 2% of all FDA-approved drugs have been taken off the market to due to safety concerns.
Unfortunately, the FDA’s process has produced a system where a drug takes 12 years on average to be approved at an average cost of over $1 billion. These estimates do not include the FDA’s impact on pre-clinical research, which can add over a decade to the process and additional costs.
The FDA approves a relatively small number of drugs each year, as shown in the following chart, and much fewer blockbusters.
In contrast, the number of compounds that can lead to better health outcomes is increasing rapidly, as shown in the following chart.
In comparing the two charts, it is obvious that the FDA cannot keep pace with technological innovation.
The government website for clinical trials lists over 270,000 research studies. However, no one prioritizes this research for any particular purpose or specific objective. Hence, there is no coordination on which promising research should be pursued for various illnesses. Certainly, the invisible hand of the market cannot create an efficient allocation of resources given the lack of coordination.
The FDA has different approval processes depending on the application. However, many have rigid requirements that frustrate researchers in pursuing specific cures. For example, the FDA requires that the compounds in cancer trials have an impact on the existing tumor. However, for trials addressing metastatic cancer, scientists would prefer that the end point for the trial be length of delay until a metastasis occurs, not the impact on an existing tumor.
In 2013, I filed a Citizens Petition with the FDA to put greater and more focused resources on metastatic cancer and to collapse its trial design requirements for this cancer from three phases to two. My petition was denied.
It is actions such as this that led the former Director of the National Cancer Institute, Vincent T. DeVita, Jr. M.D., in The Death of Cancer (2015) to recommend that the FDA should not have approval authority over Phase 1 and Phase 2 clinical trials for cancer (and, by inference, should not participate in regulating pre-clinical cancer research).
The impact and cost of delay from the FDA approval process is large. For example, in 2012, I filed a Citizen’s Petition with the FDA for it to withdraw support of ACT chemotherapy for BRCA1-related breast cancer and enable women to be treated with a PARP inhibitor and a platinum-based drug. The Petition was denied. However, this year, the FDA approved exactly such an approach. In the interim period, about 90,000 women died prematurely from the inferior treatment afforded by an antiquated standard of care.
Announcing a desire for cures is not enough. For example, it has been more than 50 years since President Nixon declared a “War on Cancer”. More recently, President Obama announced a major initiative to seek cures through precision medicine. However, when I subsequently petitioned the FDA to issue a Notice of Proposed Rulemaking seeking input on how best to analyze and approve, as appropriate, new Precision Medicine Initiatives, the FDA responded by saying it “has been unable to reach a decision on your petition due to the need to address other Agency Priorities”.
On a national scale, when looking at the magnitude of the dollars spent and/or the magnitude of the dysfunction in the current system, the greatest area for improvement in healthcare is the management and integration of the industry practices that affect chronic illnesses across all components of the industry.
Governments worldwide have recognized the importance and impact of standards on their economies. Standards have significant pro-competitive effects such as increasing price competition as standard products are more readily compared and solving issues such as product compatibility and consumer safety.
Standards bodies can be governmental, quasi-governmental or non-governmental. Quasi-governmental and non-government standards bodies are often non-profit. Quasi-governmental organizations are supported by the government but managed privately.
In the healthcare industry, we know that there is a need for:
To help achieve these objectives, a non-profit, quasi-government standards organization called the National Healthcare Standards Organization (NHSO) should be established to publish guidelines and coordinate the practices of the industry as follows:
The NHSO and each chapter would have five representatives including medical experts in the relevant field and a member of the public. The composition of the Chapter Members should represent the core medical specialties and clinical expertise involved in the specific standard of care (with exclusions for any conflicts of interests).
The NHSO and its chapters would have full-time paid staff providing logistical and content development for all matters before the NHSO. The budget of NHSO would be covered by user fees paid for by industry participants based upon company size.
An Integrated Approach for the Healthcare of Chronic Illnesses
It is not reasonable to expect an individual consumer to integrate all of the components of the healthcare industry in order to make an informed purchase of service for any one condition, let alone for multiple ailments which is often the case.
Nor is it reasonable to assume that the federal government can play this role. At a minimum, such an organization would be subject to political instability.
Nevertheless, certain practices and guidelines would require the imprimatur of the federal government to be effective.
In particular, a non-profit, quasi-government organizational approach is best suited to enable the private healthcare market to function more efficiently on behalf of the consumer.
The following chart shows how the healthcare industry should be organized to improve care and lower costs for the Top 10 chronic illnesses.
The first step for the newly-established NHSO would be to establish standards of care for each of the Top 10 illnesses and to develop short-term and long-term objectives based upon the industry resources dedicated to these illnesses.
Secondly, the chapters would define the interfaces and best practices for the various components of the industry affecting their relevant patient populations.
For example, each chapter would establish the benchmark for the basic level of insurance coverage for various procedures and treatments based on the approved standard of care. They would also prioritize the efforts for specific research initiatives. Equally important, they would establish the informational, pre-clinical and clinical requirements most appropriate for each chronic illness.
The ultimate value of the NHSO and its chapters would be to create a better functioning private market for each of the Top 10 chronic illness markets in the United States.
Summary and Conclusion
The healthcare system in the United States is grossly inefficient. As long as consumers, practitioners, manufacturers, standards and guidance bodies, insurance carriers and government practices and policies are not coordinated, healthcare services will have excessive costs and will remain overpriced and the well-being of the overall public will remain inadequate.
The inefficiencies are largest in the area of chronic illnesses. Additionally, chronic illnesses represent the least likely areas for achieving an efficient outcome in a free marketplace given the complexity and the lack of readily-available information.
This paper shows why the public and its representatives in Congress should endorse a National Healthcare Standards Organization that builds on the seeds that are already blossoming in the fields of Parkinson’s disease and hereditary cancer. The National Health Standards Organization should focus on the Top 10 chronic illnesses to ensure all of the components of the healthcare industry are working in lock step and reflect the best interests of the public regarding these illnesses.
Steven A. Zecola
Copyright © 2019 Ideas for Change - All Rights Reserved.